Almotriptan — Discount Pricing

Other medications in Pain & Inflammation

• Baclofen
• Buprenorphine
• Buprenorphine-Naloxone
• Butorphanol
• Caffeine-Ergotamine
• Capsaicin
• Capsaicin Patch
• Carisoprodol

What Almotriptan is approved for (FDA label)

Almotriptan tablets, USP are 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of almotriptan tablets on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) 1.1 Acute Treatment of Migraine Attacks Adults Almotriptan tablets, USP are indicated for the acute treatment of migraine attacks in patients with a history of migraine with or without aura.

Source: Read the full FDA label on DailyMed. Label effective date: December 31, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Almotriptan (FDA label)

Almotriptan tablets, USP are available as white, circular, biconvex, film-coated tablets in the following dosage strengths: 6.25 mg tablet debossed with ‘A1’ on one side and plain on other side. 12.5 mg tablet debossed with ‘A2’ on one side and plain on other side. Tablets: 6.25 mg and 12.5 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 6fa380c4-c885-4743-85bf-88819ae68645. SPL document ID: caa5857a-45bf-4b7d-8874-6fe2cb6eb4cf. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Almotriptan (FDA label)

Serious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD. Reactions reported in association with triptans have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation [see Contraindications ( 4.1 ) and Warnings and Precautions ( 5.1 )]. The following adverse reactions are discussed in more detail in other sections of the labeling: Risk of Myocardial Ischemia and Infarction and Other Adverse Cardiac Events [see Warnings and Precautions ( 5.1 )] Sensations of Pain, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw [see Warnings and Precautions ( 5.2 )] Cerebrovascular Events and Fatalities [see Warnings and Precautions ( 5.3 )] Other Vasospasm-Related Events, Including Peripheral Vascular Ischemia and Colonic Ischemia [see Warnings and Precautions ( 5.4 )] Serotonin Syndrome [see Warnings and Precautions ( 5.5 )] Increases in Blood Pressure [see Warnings and Precautions ( 5.7 )] Adverse events were assessed in controlled clinical trials that included 1840 adult patients who received one or two doses of almotriptan tablets and 386 adult patients who received placebo. The most common adverse reactions during treatment with almotriptan tabletswere nausea, somnolence, headache, paresthesia, and dry mouth.

Source: FDA prescribing information (DailyMed). Set ID: 6fa380c4-c885-4743-85bf-88819ae68645. SPL document ID: caa5857a-45bf-4b7d-8874-6fe2cb6eb4cf. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Almotriptan (FDA label)

Ischemic heart disease, coronary artery vasospasm, or other significant underlying cardiovascular disease ( 4.1 ) Cerebrovascular syndromes (e.g., history of stroke or TIA) ( 4.2 ) Peripheral vascular disease (including ischemic bowel disease) ( 4.3 ) Uncontrolled hypertension ( 4.4 ) Do not use almotriptan tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT 1 agonist, e.g., another triptan ( 4.5 , 4.6 ) Hemiplegic or basilar migraine ( 4.7 ) Known hypersensitivity to almotriptan tablets ( 4.8 ) 4.1 Ischemic or Vasospastic Coronary Artery Disease, or Other Significant Underlying Cardiovascular Disease Do not use almotriptan tablets in patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or in patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's variant angina, or other significant underlying cardiovascular disease [see Warnings and Precautions ( 5.1

Source: FDA prescribing information (DailyMed). Set ID: 6fa380c4-c885-4743-85bf-88819ae68645. SPL document ID: caa5857a-45bf-4b7d-8874-6fe2cb6eb4cf. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Almotriptan (FDA label)

Serious adverse cardiac events, including acute myocardial infarction and life-threatening disturbances of cardiac rhythm ( 5.1 ) It is strongly recommended that almotriptan tablets not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors. In very rare cases, serious cardiovascular events have been reported in association with almotriptan tablets use in the absence of known cardiovascular disease. If almotriptan tablets are considered, patients should first have a cardiovascular evaluation.

Source: FDA prescribing information (DailyMed). Set ID: 6fa380c4-c885-4743-85bf-88819ae68645. SPL document ID: caa5857a-45bf-4b7d-8874-6fe2cb6eb4cf. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Almotriptan (FDA label)

Do not use almotriptan tablets and ergotamine-containing or ergot-type medications within 24 hours of each other ( 4.5 , 7.1 ) Do not use almotriptan tablets and other 5-HT 1 agonists (e.g., triptans) within 24 hours of each other ( 4.6 , 7.2 ) SSRI or SNRI: life-threatening serotonin syndrome reported during combined use with triptans ( 5.5 , 7.3 ) Ketoconazole: use single dose of almotriptan tablets 6.25 mg; maximum almotriptan tablets daily dose 12.5 mg ( 7.4 ) 7.1 Ergot-Containing Drugs These drugs have been reported to cause prolonged vasospastic reactions.

Source: FDA prescribing information (DailyMed). Set ID: 6fa380c4-c885-4743-85bf-88819ae68645. SPL document ID: caa5857a-45bf-4b7d-8874-6fe2cb6eb4cf. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.